Drug developer Targacept Inc. (NASDAQ: TRGT) and partner AstraZeneca plc (NYSE: AZN) today announced that they will not file for regulatory approval on an anti-depressant drug called TC-5214 following a trial in which the drug did no better than placebo. The writing has been on the wall on TC-5214 since an announcement in December that the drug had failed to meet its endpoint in a phase II trial.
Targacept’s CEO said that the company has been preparing for this possibility and that it will announce its plans by the end of April. The company has more than $225 million in cash available according to the CEO.
Targacept’s shares are down -27% at $5.41 in a 52-week range of $4.91-$27.22. AstraZeneca’s shares are up about 0.4% at $45.58 in a 52-week range of $40.89-$52.54.
Take This Retirement Quiz To Get Matched With A Financial Advisor (Sponsored)
Take the quiz below to get matched with a financial advisor today.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the
advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Take the retirement quiz right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
